CAMBRIDGE, Mass.--(BUSINESS WIRE)--OvaScience℠ (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, announced today that Company management will present at the JMP Securities Life Sciences Conference on Tuesday, June 23, 2015 at 9:00 am ET at the St. Regis New York.
A live audio webcast of the presentation can be accessed by visiting the Investors section of the Company’s website at www.ovascience.com. A replay of the webcast will be archived on the OvaScience website for two weeks following the presentation.
About OvaScience
OvaScience (NASDAQ: OVAS) is a global
fertility company dedicated to improving treatment options for women
around the world. OvaScience is discovering, developing and
commercializing new fertility treatments because we believe women
deserve more options. Each OvaScience treatment is based on the
Company’s proprietary technology platform that leverages the
breakthrough discovery of egg precursor (EggPC℠) cells – immature egg
cells found inside the protective ovarian lining. The
AUGMENT℠ treatment, a fertility option specifically designed to improve
egg health, is available in certain IVF clinics in select international
regions outside of the United States. OvaScience is developing the
OvaPrime℠ treatment, which could increase a woman’s egg reserve, and the
OvaTure℠ treatment, a potential next-generation IVF treatment that could
help a woman produce healthy, young, fertilizable eggs without hormone
injections. For more information, please visit www.ovascience.com and
connect with us on Twitter
and Facebook.
Forward-Looking Statements
This press release includes
forward-looking statements about the Company’s plans for the AUGMENT
treatment and two fertility treatments in development. Actual results
may differ materially from those indicated by these forward-looking
statements as a result of various important factors, including risks
related to: the possibility that international IVF clinics that we work
with may determine not to begin or continue providing the AUGMENT
treatment for commercial or other reasons; our expectation that the
AUGMENT treatment and OvaPrime treatment meet the requirements of a
class of products exempt from premarket review and approval under
applicable regulations in those countries where we have launched or plan
to introduce the AUGMENT treatment and plan to introduce the OvaPrime
treatment; the commercial ramp up of the AUGMENT treatment, which we
expect will depend upon the successful transition of ACE clinics to
commercial operations, the addition of new ACE clinics, and the results
from ACE clinic experience as they become available; the science
underlying our treatment and treatments in development (including the
AUGMENT, OvaPrime and OvaTure treatments), which is unproven; our
ability to obtain regulatory approval where necessary for our potential
treatments; our ability to develop our potential treatments, including
the OvaPrime and OvaTure treatments, on the timelines we expect, if at
all; our ability to commercialize the AUGMENT treatment and our
potential treatments, including the OvaPrime treatment, on the timelines
we expect, if at all; as well as those risks more fully discussed in the
“Risk Factors” section of our most recently filed Quarterly Report on
Form 10-Q and/or Annual Report on Form 10-K. The forward-looking
statements contained in this press release reflect our current views
with respect to future events. We anticipate that subsequent events and
developments will cause our views to change. However, while we may elect
to update these forward-looking statements in the future, we
specifically disclaim any obligation to do so. These forward-looking
statements should not be relied upon as representing our view as of any
date subsequent to the date hereof.
###